<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00119626</url>
  </required_header>
  <id_info>
    <org_study_id>SA-NXY-0006</org_study_id>
    <secondary_id>0006</secondary_id>
    <secondary_id>SAINT I</secondary_id>
    <nct_id>NCT00119626</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke</brief_title>
  <official_title>SAINT I (Stroke - Acute Ischemic - NXY Treatment) A Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter, Phase IIb/III Study to Assess the Efficacy and Safety of Intravenous NXY-059 in Acute Ischemic Stroke.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      This study will determine if NXY-059 will reduce functional disability from an acute stroke.
      The study is designed to look at both overall recovery and recovery of motor function, for
      example muscle strength and coordination.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">February 2005</completion_date>
  <primary_completion_date type="Actual">February 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Global disability on modified Rankin scale at 90 days.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>NIH stroke scale (termed &quot;co-primary&quot; in study protocol), Barthel Index, Stroke Impact Scale, EQ-5D all at 90 days, Safety outcomes.</measure>
  </secondary_outcome>
  <enrollment>1700</enrollment>
  <condition>Cerebral Stroke</condition>
  <condition>Ischemic Attack, Transient</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NXY-059</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females

          -  Acute ischemic stroke with limb weakness, onset of symptoms within 6 hours

          -  Full functional independence prior to the present stroke

        Exclusion Criteria:

          -  Unconsciousness

          -  Subjects who are unlikely to complete the infusion of investigational product and/or
             are unlikely to undergo active medical management during that period due to a severe
             clinical condition

          -  Severe illness with life expectancy less than 6 months

          -  Known severe kidney disorder

          -  Current known alcohol or illicit drug abuse or dependence

          -  Pregnant or breast-feeding

          -  Treatment with acetazolamide and methotrexate is not permitted during the infusion

          -  Participation in a previous clinical study within 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AstraZeneca NXY-059 Medical Science Director, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Södertälje</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Diener HC, Grotta J, Lyden P, Shuaib A, Hårdemark HG, Wasiewski WW; Stroke-Acute Ischemic NXY Treatment (SAINT I) Trial Investigators. NXY-059 for acute ischemic stroke. N Engl J Med. 2006 Feb 9;354(6):588-600.</citation>
    <PMID>16467546</PMID>
  </results_reference>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2005</study_first_submitted>
  <study_first_submitted_qc>July 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2005</study_first_posted>
  <last_update_submitted>November 10, 2010</last_update_submitted>
  <last_update_submitted_qc>November 10, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2010</last_update_posted>
  <keyword>Stroke, Acute</keyword>
  <keyword>Cerebrovascular Stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Ischemic Attack, Transient</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disufenton sodium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

